Stéphane Bancel defended his melanoma data and argued that rivals can’t easily copy the technology.

Moderna shares have outperformed tech giants this year.

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real ...

Moderna released full data on its closely watched cancer vaccine developed with Merck.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is ...

Moderna (MRNA) stock falls as William Blair downgrades the biotech, citing valuation concerns after a trial win for its Merck ...

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with ...